Company intelligence / Profile preview
Surface Ophthalmics
Pleasanton, California, United Statessurfaceophthalmics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has conducted Phase II clinical trials for multiple programs with over 550 patients across more than 50 U.S. clinical sites. SURF-201 showed positive top-line results in Phase II for post-cataract surgery pain and inflammation as announced in January 2021[5].
- Therapeutic areas
- Ophthalmology
- Modalities
- Topical eye dropsOral capsules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Surface Ophthalmics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Surface Ophthalmics.